跳轉至內容
Merck
全部照片(1)

重要文件

SML2401

Sigma-Aldrich

Imeglimin hydrochloride

≥98% (HPLC), powder, anti-hyperglycemic compound

同義詞:

(6R)-1,6-dihydro-N,N,6-trimethyl-1,3,5-Triazine-2,4-diamine Hydrochloride,, (6R)-3,6-Dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, EMD 387008 Hydrochloride, EMD-387008 Hydrochloride, R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine Hydrochloride

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C6H13N5 · xHCl
CAS號碼:
分子量::
155.20 (free base basis)
分類程式碼代碼:
12352200
NACRES:
NA.77

產品名稱

Imeglimin hydrochloride, ≥98% (HPLC)

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

H2O: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

Cl.N1[C@@H](N=C(N=C1N(C)C)N)C

InChI

1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1

InChI 密鑰

UXHLCYMTNMEXKZ-PGMHMLKASA-N

相關類別

生化/生理作用

Glucose-lowering agent that appears to target mitochondrial bioenergetics
Imeglimin is a first-in-class oral glucose-lowering agent whose mechanism of action targets mitochondrial bioenergetics, resulting in increased insulin secretion in response to glucose, improved glucose uptake by skeletal muscle, and suppression of gluconeogenesis. Imeglimin has been shown to decrease reactive oxygen species overproduction and delay mPTP opening, preventing cell death during oxidative stress, protecting beta-cells. In an animal model, it has been shown to reduce metabolic syndrome-related diabetic cardiomyopathy.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

P577 Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Lachaux M, Hamzaoui M, Nicol L, Fouqueray P, Bolze S, Hallakou-Bozec S, Richard V, Mulder P
European Heart Journal, 38 (2017)
D Detaille et al.
Cell death discovery, 2, 15072-15072 (2016-08-24)
Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of β-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務